Trial Profile
A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Trichuris suis ova (Primary)
- Indications Autistic disorder
- Focus Therapeutic Use
- Sponsors Fortress Biotech
- 03 Nov 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 May 2014 New trial record